The 2026 tau imaging news may make Alzheimer's workups clearer about disease stage, not shorter. Memory-clinic patients with a positive p-tau blood result will generally still need PET or spinal-fluid confirmation, while tau PET helps doctors interpret how far tau spread has gone.
Tau PET is a brain scan that maps neurofibrillary tangles, twisted tau proteins that build up in Alzheimer's. According to a Lantheus Holdings press release, the FDA approved its tracer TAUKLARIFY on Aug. 14, 2026 for adults with cognitive impairment being evaluated for Alzheimer's the FDA approval announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the new tau scan add?
- Why does a positive blood test still need a second test?
- How does tau information change the result conversation?
- When can tau results mislead?
- What should you ask at the result visit?
- Frequently Asked Questions
What does the new tau scan add?
TAUKLARIFY uses florquinitau F 18, also called MK-6240, to identify tau tangle pathology during the Alzheimer's evaluation. It is the second FDA-cleared tau PET tracer after Tauvid from 2020. Its label limits use to suspected Alzheimer's workups.
In same-person imaging reported by Being Patient on a Lancet study, MK-6240 detected tangles earlier than Tauvid and supported more accurate staging the head-to-head comparison. Earlier detection here means visible signal at a lower burden of tau. Better staging means a clearer read of limited versus widespread spread.
Why does a positive blood test still need a second test?
Blood tests estimate amyloid pathology, one early Alzheimer's signal. By August 2026, the FDA had cleared four such tests, including Roche Elecsys pTau217 for symptomatic adults 55 and older. They are not standalone diagnoses or screening tests for people without symptoms.
The Alzheimer's Association 2025 guideline says qualifying blood tests may triage patients in specialty care, with positive results confirmed by spinal fluid or amyloid PET the clinical practice guideline. The triage threshold is at least 90% sensitivity and 75% specificity. In practice, a positive p-tau217 result starts the confirmation step rather than finishing the workup.
How does tau information change the result conversation?
Amyloid answers whether Alzheimer's pathology is likely present. Tau adds where the disease may stand. A limited medial-temporal signal, a wider cortical pattern, and a negative tau read can lead to different next steps even when amyloid is positive.
That distinction matters for planning follow-up, safety, and treatment eligibility discussions. It can also prompt review of sleep, medications, mood, hearing, and vascular risks that affect thinking. Ask how the scan pattern fits symptoms, function, and prior blood or spinal-fluid results.
When can tau results mislead?
Tau PET cannot distinguish non-Alzheimer's tau diseases. Safety and effectiveness are not established for those tauopathies, so doctors must read the scan only within a suspected-Alzheimer's evaluation.
UK specialist guidance makes the same point for blood testing. Plasma p-tau217 is the test of choice only within a full specialist assessment when cognitive impairment is measurable and Alzheimer's is suspected. Outside that setting, false reassurance and false alarm both become more likely.
What should you ask at the result visit?
Bring a companion, a symptom timeline, and a full medication list. Ask for plain-language answers and written results.
- Was my blood result positive, borderline, or negative, and what confirmation do I need?
- Did amyloid testing confirm Alzheimer's pathology, and what did tau imaging show about spread?
- Could another tau condition, vascular disease, or medication explain part of my symptoms?
- What follow-up, safety planning, and retesting interval do you advise for me?
Frequently Asked Questions
Will every memory concern now lead to tau PET?
No. Evaluation starts with history, cognitive testing, and often blood triage, with PET or spinal fluid reserved to confirm unclear or treatment-relevant cases.
Does a negative tau scan rule out Alzheimer's?
No. It revises the stage and certainty, but doctors interpret it with amyloid results, symptoms, and other causes of impairment.
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: Result Interpretation Questions for Memory Clinic Patients
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: Result Interpretation Questions for Memory Clinic Patients
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Result Interpretation Questions for Memory Clinic Patients
